Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer, Lilly To Revive Antibody Drug

by Ann M. Thayer
November 4, 2013 | A version of this story appeared in Volume 91, Issue 44

Pfizer will work with Eli Lilly & Co. to continue development of tanezumab, a monoclonal antibody it developed for osteoarthritis, back pain, and cancer pain. In 2010, FDA put a partial hold on clinical development of tanezumab because of adverse side effects. FDA may allow trials to restart, pending Pfizer’s submission of nonclinical data in the first half of 2014. A payment by Lilly to Pfizer is contingent on a continuation of the collaboration after FDA responds to the data. Lilly also will make payments to Pfizer for achieving clinical, regulatory, and commercial milestones.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.